, related to Figure 2. UBC13 downregulation in U2OS cells leads to unrestrained replication fork progression and reduced reversed fork frequency upon genotoxic treatments. (A) U2OS cell lines stably carrying either the wild type (Ubr-WT) or the K63R (Ubr-K63R) ubiquitin replacement system (Xu et al, 2009 ) were treated with doxycycline for different time points to induce the simultaneous knockdown of endogenous ubiquitin and expression of ectopic version. Anti-ubiquitin immunoblotting reveals that -72h after induction of knowckdown/expression (conditions used in Figure 2A -B) -comparable levels of ubiquitin conjugates are present in Ubr-WT and Ubr-K63R expressing cells. Lamin A/C is used as loading control. (B) Cell cycle distribution analysis by FACS using DAPI for the same cells as in Figure S2A . (C) EdU-DAPI FACS experiment showing marginal differences in cell cycle distribution, between wild type (WT) or UBC13 knock out (KO) HCT116 cells (see Figure 2) . (D) Western Blot showing efficiency of siRNA-mediated UBC13 downregulation in U2OS cells. GAPDH, loading control. (E) Control (siLuc) or UBC13-depleted (siUBC13) U2OS cells were subjected to the DNA fiber protocol as in Figure 1A upon optional mitomycin C (200 nM) treatment. At least one hundred tracks were scored per sample. Whiskers: 10-90th percentile (****, P < 0.0001; **, P < 0.05; Mann -Whitney test). Very similar results were obtained in at least two biological replicates. (F) Frequency of replication fork reversal in control (siLuc) or UBC13-depleted (siUBC13) U2OS cells, assessed by in vivo psoralencrosslinking and EM visualization, upon optional 1h treatment with CPT 50 nM or MMC 200 nM. In brackets, the number of analyzed molecules. Very similar results were obtained in two biological replicates (Table S2C ). Figure 1A . At least one hundred tracks were scored per sample. Whiskers: 10-90th percentile (****, P < 0.0001; ns, non-significant, Mann -Whitney test). Similar results were obtained in at least two biological replicates. (C) Frequency of replication fork reversal in WT and ZRANB3-KO U2OS cells, assessed by in vivo psoralen-crosslinking and EM visualization, upon optional 1h treatment with CPT 50 nM. In brackets, the number of analyzed molecules. Similar results were obtained in two biological replicates and in two independent ZRANB3-KO clones (Tables S3A-B) . (D) Western Blot showing efficiency of siRNA-mediated ZRANB3 downregulation in U2OS cells. β tubulin, loading control. (E) Control (siLuc) or ZRANB3-depleted (siZRANB3) U2OS cells were subjected to the DNA fiber protocol as in Figure 1A , upon optional treatments with MMC 200 nM (left) or CPT 50 nM (right). At least one hundred tracks were scored per sample. Whiskers: 10-90th percentile (****, P < 0.0001; *, P < 0.5; Mann -Whitney test). Very similar results were obtained in at least two biological replicates. (F) Frequency of replication fork reversal in control (siLuc) or ZRANB3-depleted (siZRANB3) U2OS cells, assessed by in vivo psoralen-crosslinking and EM visualization, upon optional 1h treatment with CPT 50 nM or MMC 200 nM. In brackets, the number of analyzed molecules. Very similar results were obtained in two biological replicates (Table S3C ). Figure 4 ). (C-E) Acute genotoxic treatments and genetic impairment of joint-molecule dissolution do not lead to detectable accumulation of post-replicative sister-chromatid junctions in human cells. Rationale: Depending on repair/replication kinetics and lesion type, cells can tolerate DNA impediments at or behind the replication fork. Lesion bypass at the fork is achieved by switching to a translesion synthesis polymerase (TLS) or by template switching through fork reversal. Single strand gaps behind the fork can be sealed by TLS or by template switching via post-replicative junctions. In Saccharomyces cerevisiae, postreplicative template switching has been extensively studied. X-shaped structures representing post-replicative junctions accumulate in specific genetic conditions, in particular upon impairment of their dissolution by deletion of the yeast RecQ helicase Sgs1 (Branzei et al., 2006; Liberi et al., 2005) . Using high-copy number linear minichromosomes, these X-shaped structures were selectively isolated from 2D gels and studied by TEM (Giannattasio et al., 2014) . Data: To visualize post-replicative junctions in human cells, we took advantage of an SV40-based episomal system that replicates with very high efficiency and allows isolation of in vivo replication intermediates (Follonier and Lopes, 2014; Follonier et al., 2013) . However, neither low (C) nor high (D) dose of various genotoxic treatments did induce detectable accumulation of X-shaped structures, over levels usually detected in untreated cells (arrow). (E) Furthermore, X-shaped structures did not accumulate after downregulation of the human Sgs1 homolog Bloom syndrome protein (BLM), which has been shown to dissolve sister chromatid junctions in human cells (Wu and Hickson, 2003) . These data strongly suggest that, contrary to yeast, template switching in human cells occurs primarily at the replication for via fork reversal, which is indeed very abundantly detected and dependent upon error-free PRR factors (see main text). Method: Neutralneutral 2D-gel analysis of plasmid pML113 transfected into untreated (NT) HEK-293T cells and upon 1 h treatment with the indicated dose of genotoxic drugs. Plasmid was recovered after 40 h and digested by EcoRI as indicated. 2D gel analysis was performed as described (Follonier and Lopes, 2014) ; the probe reveals replication intermediates in the gray fragment (top left scheme; circle, SV40 replication origin). APH=Aphidicolin, HU=Hydroxyurea, MMS=Methyl Methanesulfonate, H2O2=Hydrogen Peroxide, UV=UV-C irradiation, CPT=Camptothecin, ETP=Etoposide, Doxo=Doxorubicin, MMC=Mitomycin C, CDDP=Cisplatin. Bloom (BLM) levels after siRNA-mediated depletion were detected by immunoblotting. TFIIH, loading control. 4 (75) 29 (92) 26 (87) 12 (75) 11 (79) 10 (80) % RF Exp #2
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